COST: Utilization management Our prior authorization (PA) criteria for GLP-1s are based on FDA-approved labeling and clinical compendia
Peptides 54, 1926
This is particularly relevant given that obesity and T2DM themselves are risk factors for pancreatitis.44,45 Additionally, the prescription of GLP-1RAs is often associated with poor glycaemic control, which could be caused by occult pancreatic diseases.46,47 The treatment selection process introduces intrinsic sources of imbalance and confounding, leading to potential distortions in the results
It's slow, steady work over many, many years
If a patient on both drugs experiences palpitations or chest discomfort, clinicians cannot easily attribute the symptom to one agent, complicating dose adjustment or discontinuation decisions
a control group consisting of patients medicated with other glucose-lowering drugs (SMD 0.45